A Phase 4 interventional study of Peginterferon alfa-2a in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 6 sites in New Zealand. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-02-06.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 51st largest by enrollment, is one of 5 that started in 2006, is one of 29 in phase 4, and was the 47th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 29th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2006, is one of 16 in phase 4, and was the 41st registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an expanded access, multicenter, national, open-label, and non-randomized study to analyze the safety of peginterferon alfa-2a in participants with hepatitis B e antigen (HBeAg) positive and HBeAg negative chronic HBV infection. All participants will receive 48 weeks treatment of peginterferon alfa-2a monotherapy, followed by a 24 week treatment-free follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
Drug: Peginterferon alfa-2a
HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
Drug: Peginterferon alfa-2a
180 mcg SC injection QW for 48 weeks.
Also known as: Pegasys
Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)
HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.
Time frame: End of 24-weeks follow-up (Week 72)
Number of Participants With HBV-DNA <20,000 Copies/mL
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
Time frame: End of 24-weeks follow-up (Week 72)
Number of Participants With HBV-DNA <400 Copies/mL
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.
Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)
Number of Participants With Normalization of Alanine Aminotransferase (ALT) Level
ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases. Normal ALT level = less than upper limit of normal (40 units per liter).
Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)
Number of Participants With HBeAg Seroconversion
HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).
Time frame: Week 48 (end of treatment) and Week 72 (end of follow-up)
| Milestone | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| Started | 4 | 20 |
| Completed | 4 | 19 |
| Not completed | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.
| participants | HBeAg Positive Participants |
|---|---|
| Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL) | 7 |
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
| participants | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| Number of Participants With HBV-DNA <20,000 Copies/mL | 0 | 3 |
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
| participants | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| Week 48 (n=4,18) | 3 | 6 |
| Week 72 (n=3,17) | 0 | 2 |
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.
| participants | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| Week 48 (n=4,15) | 0 | 0 |
| Week 72 (n=4,13) | 0 | 0 |
ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases. Normal ALT level = less than upper limit of normal (40 units per liter).
| participants | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| Week 48 (n=4,19) | 2 | 4 |
| Week 72 (n=4,17) | 4 | 7 |
HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).
| participants | HBeAg Positive Participants |
|---|---|
| Week 48 (n=19) | 6 |
| Week 72 (n=17) | 6 |
Collected over Baseline up to end of follow-up period (Approximately 72 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HBeAg Negative Participants | — | 1/4 (25%) | 3/4 (75%) |
| HBeAg Positive Participants | — | 0/20 (0%) | 7/20 (35%) |
| Event | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| chest painCardiac disorders | 1/4 | 0/20 |
| Event | HBeAg Negative Participants | HBeAg Positive Participants |
|---|---|---|
| DepressionNervous system disorders | 2/4 | 1/20 |
| Mood disturbanceNervous system disorders | 1/4 | 1/20 |
| TirednessGeneral disorders | 1/4 | 1/20 |
| RashSkin and subcutaneous tissue disorders | 1/4 | 0/20 |
| Non-productive coughRespiratory, thoracic and mediastinal disorders | 1/4 | 0/20 |
| InsomniaPsychiatric disorders | 1/4 | 0/20 |
| Urinary frequencyRenal and urinary disorders | 1/4 | 0/20 |
| Itchy skinSkin and subcutaneous tissue disorders | 0/4 | 1/20 |
| HypothyroidismEndocrine disorders | 0/4 | 1/20 |
| GlaucomaEye disorders | 0/4 | 1/20 |
Safety analysis population included participants who received at least one dose of study medication and had one subsequent post baseline safety assessment.
| Age, Continuous(years) | HBeAg Negative Participants | HBeAg Positive Participants | Total |
|---|---|---|---|
| Mean | 43.25 ± 5.75 | 31.57 ± 9.43 | 33.52 ± 9.88 |
| Gender(Participants) | HBeAg Negative Participants | HBeAg Positive Participants | Total |
|---|---|---|---|
| Female | 0 | 7 | 7 |
| Male | 4 | 13 | 17 |
The record gives a start of Jan 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2017, 8 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a